Current Report Filing (8-k)
May 14 2019 - 4:52PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported):
May 14, 2019
CYTORI THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
001-34375
|
33-0827593
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File
Number)
|
(I.R.S. Employer Identification Number)
|
3020 Callan Road, San Diego, California 92121
(Address of principal executive offices, with zip code)
(858) 458-0900
(Registrant's telephone number, including area code)
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
|
|
|
|
□
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
□
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
□
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
□
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by
check
mark whether
the
registrant
is
a
n
emerging
growth
company
as
defined
in
Rule
405
of the
Securities Act
of
1933
(§
230.405
of
this
chapter)
or
Rule
12b-2
of
the
Securities
Exchange
Act
of
1934
(§
240.12b-2
of
this
chapter).
Emerging
growth
company
□
If an emerging growth company,
indi
c
a
te
by
check
mark
if
the
registrant
has
elected
not to use the
e
x
tended
transition
period
for complying
with
any
new
or
re
v
ised
financial
accounting
standards
pro
v
ided
pursuant
to
Section
13(a)
of
the
E
x
change
Act.
□
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.001
|
CYTX
|
Nasdaq Capital Market
|
Item 2.02
Results of Operations and Financial Condition
On
May
14, 2019, Cytori Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2019. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The information disclosed under this Item 2.02 in this report, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
Item 9.01
Financial Statements and Exhibits
(d)
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
CYTORI THERAPEUTICS, INC.
|
|
|
Date: May 14, 2019
|
By: /s/ Gary Titus
|
|
Gary Titus
|
|
Chief Financial Officer
|
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Sep 2023 to Sep 2024